Riskpilot← Back to searchSign inGet full accessVanadis ApS
APSActiveCVR 37156833Gyldenlundsvej 21, 1.Research and experimental development on natural sciences and engineering · NACE 7210Est. 20151 employeeswww.vanadis.dk
Revenue 2024
DKK -28K
-34% vs 2023
EBITDA margin
223.3%
+19% vs 2023
Equity ratio
-578.0%
Financial strength
Net profit 2024
DKK -63K
+19% vs 2023
| Revenue | DKK -28K | -34% |
| EBITDA | DKK -63K | +19% |
| Net profit | DKK -63K | +19% |
| Total assets | DKK 409K | -7% |
| Equity | DKK -2,4M | -3% |
| Employees | 1 | — |
Legal name
Vanadis ApS
CVR number
37156833
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
12. oktober 2015
Share capital
DKK 50.000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af én direktør.
Company purpose
Selskabets formål er at udvikle, registrere og kommercialisere nye generiske produkter til den pharmaceutiske industri samt anden hermed beslægtet virksomhed.
Address
Gyldenlundsvej 21, 1.
Phone
+4551868482
Email
bt@vanadis.dk
Website
www.vanadis.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 185 | 12 | -93 | 87 | -39 | -70 | -49 | -43 | -28 |
| Staff expenses | -1.036 | -671 | -845 | -79 | -60 | -35 | -34 | -34 | -35 |
| EBITDA | -851 | -659 | -938 | 8 | -99 | -105 | -83 | -77 | -63 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -851 | -659 | -938 | 8 | -99 | -105 | -83 | -77 | -63 |
| Net financials | -1 | -1 | -0 | -0 | -0 | -1 | -0 | 0 | -0 |
| Profit before tax | -852 | -660 | -938 | 8 | -99 | -105 | -83 | -77 | -63 |
| Tax | -184 | -152 | -218 | -0 | -0 | -0 | 97 | -0 | -0 |
| Net profit | -668 | -508 | -720 | 8 | -99 | -105 | -181 | -77 | -63 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 655 | 1.148 | 701 | 672 | 578 | 471 | 487 | 440 | 409 |
| Equity | -618 | -1.126 | -1.846 | -1.838 | -1.937 | -2.043 | -2.223 | -2.300 | -2.363 |
| Long-term debt | 1.200 | 2.200 | 2.500 | 2.500 | 2.500 | 2.500 | 2.697 | 2.697 | 2.697 |
| Short-term debt | 73 | 74 | 48 | 10 | 15 | 14 | 13 | 43 | 75 |
| Total debt | 1.273 | 2.274 | 2.548 | 2.510 | 2.515 | 2.514 | 2.710 | 2.740 | 2.772 |
EBITDA margin
-6257700.0%
This company
15.8%
Market median
-39605796% vs market
20162024
Equity ratio
-578.0%
This company
38.2%
Market median
-1613% vs market
20162024
Return on equity
-6258000.0%
This company
18.4%
Market median
-34010970% vs market
20162024
Net profit margin
-6258000.0%
This company
8.1%
Market median
-77259359% vs market
20162024
Asset turnover
-0.07×
This company
1.12×
Market median
-106% vs market
20162024
Debt / equity
1.17×
This company
0.62×
Market median
-89% vs market
20162024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2015-10-12 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
BT Management | Management | 2015 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
HELLERUNG ApS | Company | 50.0% | 50.0% | 2015 |
COMMERCE PHARMA HOLDING ApS | Company | 33.3% | 33.3% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
HELLERUNG ApS
Vanadis ApS Board members of Vanadis ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Bo Tandrup | Management | 0 companies |